These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 14661056)

  • 1. RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Oncogene; 2004 Feb; 23(8):1539-48. PubMed ID: 14661056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells.
    Duxbury MS; Ito H; Zinner MJ; Ashley SW; Whang EE
    Clin Cancer Res; 2004 Apr; 10(7):2307-18. PubMed ID: 15073106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differential processing of let-7a precursors influences RRM2 expression and chemosensitivity in pancreatic cancer: role of LIN-28 and SET oncoprotein.
    Bhutia YD; Hung SW; Krentz M; Patel D; Lovin D; Manoharan R; Thomson JM; Govindarajan R
    PLoS One; 2013; 8(1):e53436. PubMed ID: 23335963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.
    Tu M; Li H; Lv N; Xi C; Lu Z; Wei J; Chen J; Guo F; Jiang K; Song G; Gao W; Miao Y
    Mol Cancer; 2017 Mar; 16(1):66. PubMed ID: 28327155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine-based chemogene therapy for pancreatic cancer using Ad-dCK::UMK GDEPT and TS/RR siRNA strategies.
    Réjiba S; Bigand C; Parmentier C; Hajri A
    Neoplasia; 2009 Jul; 11(7):637-50. PubMed ID: 19568409
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.
    Xie H; Lin J; Thomas DG; Jiang W; Liu X
    Int J Clin Exp Pathol; 2012; 5(4):347-55. PubMed ID: 22670179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pegylated arginine deiminase synergistically increases the cytotoxicity of gemcitabine in human pancreatic cancer.
    Daylami R; Muilenburg DJ; Virudachalam S; Bold RJ
    J Exp Clin Cancer Res; 2014 Dec; 33(1):102. PubMed ID: 25499121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2).
    Xia G; Wang H; Song Z; Meng Q; Huang X; Huang X
    J Exp Clin Cancer Res; 2017 Aug; 36(1):107. PubMed ID: 28797284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F; Li Causi E; Rodriguez-Justo M; Goodstal S; Hagemann T; Hartley JA; Hochhauser D
    Clin Cancer Res; 2015 Dec; 21(24):5563-77. PubMed ID: 26228206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas.
    Itoi T; Sofuni A; Fukushima N; Itokawa F; Tsuchiya T; Kurihara T; Moriyasu F; Tsuchida A; Kasuya K
    J Gastroenterol; 2007 May; 42(5):389-94. PubMed ID: 17530364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.
    Fujita H; Ohuchida K; Mizumoto K; Itaba S; Ito T; Nakata K; Yu J; Kayashima T; Souzaki R; Tajiri T; Manabe T; Ohtsuka T; Tanaka M
    Neoplasia; 2010 Oct; 12(10):807-17. PubMed ID: 20927319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNA interference targeting focal adhesion kinase enhances pancreatic adenocarcinoma gemcitabine chemosensitivity.
    Duxbury MS; Ito H; Benoit E; Zinner MJ; Ashley SW; Whang EE
    Biochem Biophys Res Commun; 2003 Nov; 311(3):786-92. PubMed ID: 14623342
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MiR-20a-5p regulates gemcitabine chemosensitivity by targeting RRM2 in pancreatic cancer cells and serves as a predictor for gemcitabine-based chemotherapy.
    Lu H; Lu S; Yang D; Zhang L; Ye J; Li M; Hu W
    Biosci Rep; 2019 May; 39(5):. PubMed ID: 30777929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-κB signaling pathway in human pancreatic ductal adenocarcinoma.
    Chen D; Niu M; Jiao X; Zhang K; Liang J; Zhang D
    Int J Mol Sci; 2012; 13(1):1186-1208. PubMed ID: 22312312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the Warburg effect with a novel glucose transporter inhibitor to overcome gemcitabine resistance in pancreatic cancer cells.
    Lai IL; Chou CC; Lai PT; Fang CS; Shirley LA; Yan R; Mo X; Bloomston M; Kulp SK; Bekaii-Saab T; Chen CS
    Carcinogenesis; 2014 Oct; 35(10):2203-13. PubMed ID: 24879635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase M2 is a promising molecular target for the treatment of oral squamous cell carcinoma.
    Iwamoto K; Nakashiro K; Tanaka H; Tokuzen N; Hamakawa H
    Int J Oncol; 2015 May; 46(5):1971-7. PubMed ID: 25738429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of ribonucleotide reductase subunit M2 enhances the radiosensitivity of metastatic pancreatic neuroendocrine tumor.
    Chow Z; Johnson J; Chauhan A; Jeong JC; Castle JT; Izumi T; Weiss H; Townsend CM; Schrader J; Anthony L; Yang ES; Evers BM; Rychahou P
    Cancer Lett; 2024 Aug; 596():216993. PubMed ID: 38801884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HMGA1 is a molecular determinant of chemoresistance to gemcitabine in pancreatic adenocarcinoma.
    Liau SS; Whang E
    Clin Cancer Res; 2008 Mar; 14(5):1470-7. PubMed ID: 18316571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small interfering RNA (siRNA)-mediated silencing of the M2 subunit of ribonucleotide reductase: a novel therapeutic strategy in ovarian cancer.
    Zhang M; Wang J; Yao R; Wang L
    Int J Gynecol Cancer; 2013 May; 23(4):659-66. PubMed ID: 23466567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Down-regulation of deoxycytidine kinase enhances acquired resistance to gemcitabine in pancreatic cancer.
    Ohhashi S; Ohuchida K; Mizumoto K; Fujita H; Egami T; Yu J; Toma H; Sadatomi S; Nagai E; Tanaka M
    Anticancer Res; 2008; 28(4B):2205-12. PubMed ID: 18751396
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.